197 related articles for article (PubMed ID: 27989416)
1. Towards the development of activity-based probes for detection of lysine-specific demethylase-1 activity.
Ourailidou ME; Lenoci A; Zwergel C; Rotili D; Mai A; Dekker FJ
Bioorg Med Chem; 2017 Feb; 25(3):847-856. PubMed ID: 27989416
[TBL] [Abstract][Full Text] [Related]
2. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059
[TBL] [Abstract][Full Text] [Related]
3. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S
Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189
[TBL] [Abstract][Full Text] [Related]
4. Discovery of new tranylcypromine derivatives as highly potent LSD1 inhibitors.
Huang MJ; Guo JW; Fu YD; You YZ; Xu WY; Song TY; Li R; Chen ZT; Huang LH; Liu HM
Bioorg Med Chem Lett; 2021 Jun; 41():127993. PubMed ID: 33775841
[TBL] [Abstract][Full Text] [Related]
5. Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation.
Fioravanti R; Romanelli A; Mautone N; Di Bello E; Rovere A; Corinti D; Zwergel C; Valente S; Rotili D; Botrugno OA; Dessanti P; Vultaggio S; Vianello P; Cappa A; Binda C; Mattevi A; Minucci S; Mercurio C; Varasi M; Mai A
ChemMedChem; 2020 Apr; 15(7):643-658. PubMed ID: 32003940
[TBL] [Abstract][Full Text] [Related]
6. Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors.
Benelkebir H; Hodgkinson C; Duriez PJ; Hayden AL; Bulleid RA; Crabb SJ; Packham G; Ganesan A
Bioorg Med Chem; 2011 Jun; 19(12):3709-16. PubMed ID: 21382717
[TBL] [Abstract][Full Text] [Related]
7. Development and Structural Evaluation of N-Alkylated trans-2-Phenylcyclopropylamine-Based LSD1 Inhibitors.
Niwa H; Sato S; Handa N; Sengoku T; Umehara T; Yokoyama S
ChemMedChem; 2020 May; 15(9):787-793. PubMed ID: 32166890
[TBL] [Abstract][Full Text] [Related]
8. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM
J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269
[TBL] [Abstract][Full Text] [Related]
9. CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1.
Lynch JT; Cockerill MJ; Hitchin JR; Wiseman DH; Somervaille TC
Anal Biochem; 2013 Nov; 442(1):104-6. PubMed ID: 23911524
[TBL] [Abstract][Full Text] [Related]
10. Heterocycle-containing tranylcypromine derivatives endowed with high anti-LSD1 activity.
Fioravanti R; Rodriguez V; Caroli J; Chianese U; Benedetti R; Di Bello E; Noce B; Zwergel C; Corinti D; Viña D; Altucci L; Mattevi A; Valente S; Mai A
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):973-985. PubMed ID: 35317680
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
[TBL] [Abstract][Full Text] [Related]
12. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.
Zheng YC; Yu B; Jiang GZ; Feng XJ; He PX; Chu XY; Zhao W; Liu HM
Curr Top Med Chem; 2016; 16(19):2179-88. PubMed ID: 26881714
[TBL] [Abstract][Full Text] [Related]
13. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1 .
Mimasu S; Umezawa N; Sato S; Higuchi T; Umehara T; Yokoyama S
Biochemistry; 2010 Aug; 49(30):6494-503. PubMed ID: 20568732
[TBL] [Abstract][Full Text] [Related]
14. QSAR Modeling, Molecular Docking and Molecular Dynamics Simulations Studies of Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Anticancer Agents.
Abdizadeh R; Heidarian E; Hadizadeh F; Abdizadeh T
Anticancer Agents Med Chem; 2021; 21(8):987-1018. PubMed ID: 32698753
[TBL] [Abstract][Full Text] [Related]
15. Fluorinated tranylcypromine analogues as inhibitors of lysine-specific demethylase 1 (LSD1, KDM1A).
Borrello MT; Schinor B; Bartels K; Benelkebir H; Pereira S; Al-Jamal WT; Douglas L; Duriez PJ; Packham G; Haufe G; Ganesan A
Bioorg Med Chem Lett; 2017 May; 27(10):2099-2101. PubMed ID: 28390942
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M
Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860
[TBL] [Abstract][Full Text] [Related]
17. Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B.
Gooden DM; Schmidt DM; Pollock JA; Kabadi AM; McCafferty DG
Bioorg Med Chem Lett; 2008 May; 18(10):3047-51. PubMed ID: 18242989
[TBL] [Abstract][Full Text] [Related]
18. Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.
Nie Z; Shi L; Lai C; Severin C; Xu J; Del Rosario JR; Stansfield RK; Cho RW; Kanouni T; Veal JM; Stafford JA; Chen YK
Bioorg Med Chem Lett; 2019 Jan; 29(1):103-106. PubMed ID: 30409536
[TBL] [Abstract][Full Text] [Related]
19. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2.
Binda C; Valente S; Romanenghi M; Pilotto S; Cirilli R; Karytinos A; Ciossani G; Botrugno OA; Forneris F; Tardugno M; Edmondson DE; Minucci S; Mattevi A; Mai A
J Am Chem Soc; 2010 May; 132(19):6827-33. PubMed ID: 20415477
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures.
Ota Y; Kakizawa T; Itoh Y; Suzuki T
Molecules; 2018 May; 23(5):. PubMed ID: 29734782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
